Gilead (GILD) Hits New Lifetime High Today

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Gilead ( GILD) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Gilead as such a stock due to the following factors:

  • GILD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $1.0 billion.
  • GILD has traded 685,234 shares today.
  • GILD is trading at a new lifetime high.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in GILD with the Ticky from Trade-Ideas. See the FREE profile for GILD NOW at Trade-Ideas

More details on GILD:

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. GILD has a PE ratio of 20.8. Currently there are 12 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Gilead has been 11.2 million shares per day over the past 30 days. Gilead has a market cap of $139.8 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.95 and a short float of 6.2% with 9.26 days to cover. Shares are up 23.7% year-to-date as of the close of trading on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

These Stocks Pay You to Own Them

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition